Development of a broad spectrum teixobactin-lipopeptide hybrid for the treatment of lung infections caused by pan-drug resistant âsuperbugsâ
$548,207R01FY2023AINIH
University Of Southern California, Los Angeles CA
University Of Southern California, Los Angeles CA